Committed to science
Since our foundation in 1940, Grifols has helped shape industry standards in the plasma medicines sector. At the beginning of 1950, Dr. Josep Antoni Grífols i Lucas developed the plasmapheresis technique, which entails the process of extracting human plasma while simultaneously re-injecting the red blood cells back into the donor.
The plasmapheresis technique was quickly embraced by the global medical community and today remains one of the most frequently used plasma extraction techniques in blood banks and hospitals worldwide.
We became one of the first companies in the sector to implement double viral inactivation processes to produce factor VIII. Moreover, Grifols' sterile filling method has become an industry standard.
Today, we continue to innovate and at the same time support the development of the scientific community and its research efforts worldwide.
The Grifols Scientific Awards highlight our long-standing commitment to the scientific community. These recognitions promote and distinguish research in areas related to our core business.
Grants and other programs
In 2017 we allocated €5.9 million to education and scientific awards, including:
INVESTIGATOR-SPONSORED RESEARCH PROGRAM
Promote and support research that broadens the body of scientific knowledge on plasma proteins.
MEDICAL EDUCATIONAL GRANTS
The Grifols North America Medical Education Grants support independent medical-education activities to advance the professional development of healthcare providers.
GRIFOLS CHAIR FOR THE STUDY OF CIRRHOSIS
In 2015, Grifols established The Grifols Chair for the Study of Cirrhosis, an initiative with a global reach aimed at generating research and education on liver diseases, particularly cirrhosis.
We also promote the generation of knowledge internally. The work of Grifols' scientists and researchers has featured prominently in a number of prestigious publications.